DOM-ATOMOXETINE CAPSULE

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE)

Sẵn có từ:

DOMINION PHARMACAL

Mã ATC:

N06BA09

INN (Tên quốc tế):

ATOMOXETINE

Liều dùng:

60MG

Dạng dược phẩm:

CAPSULE

Thành phần:

ATOMOXETINE (ATOMOXETINE HYDROCHLORIDE) 60MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

30/100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

MISCELLANEOUS CENTRAL NERVOUS SYSTEM AGENTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0150434005; AHFS:

Tình trạng ủy quyền:

APPROVED

Ngày ủy quyền:

2012-08-16

Đặc tính sản phẩm

PRODUCT MONOGRAPH
PR
DOM-ATOMOXETINE
(ATOMOXETINE CAPSULES)
10 mg, 18 mg, 25 mg, 40 mg, and 60 mg atomoxetine, as atomoxetine
hydrochloride
Selective Norepinephrine Reuptake Inhibitor
for Attention-Deficit/Hyperactivity Disorder (ADHD)
DOMINION PHARMACAL
Date of Revision:
6111 Royalmount Ave., Suite 100
June 1, 2016
Montréal, Québec
H4P 2T4
Submission Control No: 194395
_ _
_Dom-ATOMOXETINE Product Monograph _
_Page 2 of 58_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..................................................... 3
SUMMARY PRODUCT INFORMATION
...........................................................................
3
INDICATIONS AND CLINICAL USE
.................................................................................
3
CONTRAINDICATIONS
......................................................................................................
4
WARNINGS AND PRECAUTIONS
.....................................................................................
5
ADVERSE REACTIONS
.....................................................................................................
12
DRUG ABUSE AND DEPENDENCE
................................................................................
24
DRUG INTERACTIONS
.....................................................................................................
24
DOSAGE AND ADMINISTRATION
.................................................................................
26
OVERDOSAGE
...................................................................................................................
29
ACTION AND CLINICAL PHARMACOLOGY
............................................................... 30
STORAGE AND STABILITY
.............................................................................................
34
DOSAGE FORMS, COMPOSITION AND PACKAGING
................................................ 35
PART II: SCIENTIFIC INFORMATION
...........................................................................
36
PHARMACEUTICAL INFORMATION
..